Awaiting development: Guidance and quality standards

Showing 151 to 160 of 177

Guidance and quality standards awaiting development
Title	Type
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]	Technology appraisal guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [TSID12218]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]	Technology appraisal guidance
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis [ID1396]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]	Technology appraisal guidance